¯ó¤ÙÀø¾i°|¹q¤l³øµo¦æ

­I´º¹Ï1 ­I´º¹Ï2 ­I´º¹Ï3 ­I´º¹Ï4
­I´º¹Ï5 ­I´º¹Ï6 ­I´º¹Ï7
¥Á°ê106¦~1¤ë1¤é ²Ä0156´Á
½Ã¥ÍºÖ§Q³¡¯ó¤ÙÀø¾i°| ¢x ­q¹q¤l³ø
­I´º¹Ï8 ­I´º¹Ï9 ­I´º¹Ï10
¡iµJÂIÀY±ø¡j °T®§³ø³ø
°·±d®Ñ§{
106¦~1¤ë¥÷ªù¶E½Ã¥ÍÁ¿...
106¦~1¤ë¥»°|ªù¶Eªí
¦C¦L¤å¥ó
­I´º¹Ï11 ­I´º¹Ï12 ­I´º¹Ï13
µJÂIÀY±ø
°T®§³ø³ø °T®§³ø³ø
°|ªøªº¸Ü
¡@¡@¥H¹Å¦^¨ì¬G¶m«n§ë¡u½Ã¥ÍºÖ§Q³¡¯ó¤ÙÀø¾i°|¡vªA°È¡A¤w©¡º¡¤T¦~¡C¤µ¦~¸g¥Ñ¥þÅé¦P¤¯§V¤O¡A§Ú­Ì³q¹L¦¨¬°¦Ñ¤Hºë¯«¬ì±M¬ìÂå®v°V½mÂå°|¡A¥»¤g³Ð·s¦Û³¬¯g¹êÃÒªvÀø¼Ò¦¡¤]Àò±oSNQ°ê®a«~½è¼Ð³¹»{ÃÒ¡C¦bÂå°|Àç¹B¤è­±¡A·PÁ¤j®aªº¨¯¶Ô¥I¥X¡AÅý§Ú­Ì¦³¦nªº¦¨ªø¡C¥H¤U¬O§Ú­Ì¥¼¨Ó­n§V¤Oªº­«ÂI¡C
¡@¡@¦bµwÅé¤è­±¡A§Ú­Ì«æ¯gÂåÀø¤j¼Ó¡A¤w©ó¤µ¦~6¤ë°Ê¤g¿³«Ø¡A¹w©w106¦~10¤ë©³§¹¤u¡A¥¼¨Ó¤@¦~¡A¤´µM­n½Ð©Ò¦³¥DºÞ¤Î¦P¤¯¡A¤@°_°Ñ»PºÊ·þ«æ¯g¤j¼Óªº¿³«Ø¡A¨Ã³W¹ºªø´Á·ÓÅ@ªºµo®i¡A§Æ±æ¯à´£¨Ñ¯f¤H§óÀu½è¤Î§ó§¹¾ãªºÂåÀøÀô¹Ò¡C¥t¥~¡A§Ú­Ì´X´É¼Ó¼h¡A¤]¤w³°Äò¶i¦æ¸É±j¤uµ{¡A¦p¦ó§â³o¶µ¥ô°È¶¶§Q§¹¦¨¡A¤]­n¾a¤j®a¤@°_À°¦£¡A¨Ãª`·N¤½¦@¦w¥þ¡C
¡@¡@¦b«æ­«¯gÂåÀø¤è­±¡A§Ú­Ì¾Ö¦³¤j«n§ë¦a°Ï75%«æ©Ê§É¦ì¡A¤]¾Ö¦³¤K¦¨¥H¤Wºë¯«ÂåÀø¤H­û¡A¥»°|¬°¤j«n§ë¦a°Ïºë¯«·ÓÅ@ªº«æ­«¯gÂåÀø¤¤¤ß¡A¹êÄݳdµL®Ç¶U¡C§Ú­Ì«æ¯gÂåÀø¤j¼Ó©ú¦~¸¨¦¨«á¡A¥i´£¨Ñ¸û¦nªºÂåÀø³]¬I¤ÎªA°È¡A¦AªÌ§Ú­Ì¿n·¥½Õ°t§É¦ì¤Î§ïµ½ªA°È¬yµ{¡A»P½Ã¥Í§½©Ò¤Îĵ¹î®ø¨¾¦P¤¯¥R¤À¦X§@¡AÅý«æ»Ý¦í°|ªº¯f¤H¡A§Y®É¦í°|ªvÀø¡A¸Ñ¯f¤H¤Î®aÄÝ¿U¬Ü¤§«æ¡A¤w¼sÀò¦nµû¡A¥ç¥i¼W¶iªÀ·|¦w¥þÅé¨t¤§ºûÅ@¡C
¡@¡@¦b¶ì³y±M·~«~µP¤è­±¡A¤´¶·Ä~Äò²`¤Æ´X­Ó¦¸±M¬ìªº§¹¾ãµo®i¡A°ö¾i¦U¾Ãþ®Ö¤ß¤H­û¦b¦¸±M¬ìªA°È¤Î´£¤É±M·~¯À¾i¡CÄ~103¦~§Ú­Ì³q¹L¨àµ£«C¤Ö¦~ºë¯«¬ì±M¬ìÂå®v°V½mÂå°|¡A¤µ¦~§Ú­Ì¤]¤w¶¶§Q¦¨¬°¦Ñ¤Hºë¯«¬ì±M¬ìÂå®v°V½mÂå°|¡A¾d©T¤G¤j¦¸±M¬ì°V½m°ò¦¡A¥O¤HªY¼¢¡C¦bÃÄÅ}¤è­±¡A§Ú­ÌÄ~Äò±j¤Æ­XÓy¤s²ø¬°ÃÄÅ}ªvÀø°V½m¤¤¤ß¡A¦¨¬°°ê¤º°V½mÃÄÅ}±M·~¤H­ûªº·nÄx¡C¦b¥qªk¡B®a¼É©Ê«I®`ªvÀø¤è­±¡Aµ²¦X¥»°|¯S¦³ªº¤j¨{¤s²ø¡A§Ú­Ì¤]­n¥[±j°V½m³o¤è­±ªº¤H¤~¡A±j¤ÆÁ{§É¹ê°È³B¹J¡C¤j®a­n¿n·¥«ä¦Ò¡A¦p¦ó¶i¤@¨B¸¨¹ê¥»°|¥þ­±¦¨¬°ºë¯«ÂåÀø¦¸±M¬ìªº°V½m¤¤¤ß¡C
¡@¡@¦b²`¯ÑªÀ°Ïºôµ¸¤è­±¡A§Ú­Ì¦Û103¦~¶}©l¡A«Øºc¤j«n§ë¦a°Ï13­Ó¥«¶mÂí¤ÎÁ{ªñ¥x¤¤¥«Ãú®p¤j¨½°Ï¡B¹ü¤Æ¿¤ªâ¶é¶mªºªÀ°Ïºë¯«°·±dÀç³y¡A±À¼s¤@¶mÂí¤@ªÀ°ÏªA°È¹Î¶¤¤§¬K­·­pµe¡A¤]³°Äò¶}¿ì¦Ë¤s¡B®H¨½¡B¤ô¨½¤Î«n§ë¨µ°jÂåÀøªA°È¡Aµ²¦XªÀ°Ï¤Î¦Û±þ¨¾ªvÃöÃh­û­pµe¡A¤ß²z¿Ô°Ó¯¸­pµe¡A¸¨¹êªÀ°Ï°·±dÀç³y³d¥ô°Ïªº²z©À¡A¨Ã©ó104¦~»Pºë¯«°·±d°òª÷·|¦X§@¡A¦¨¥ß«n§ëºë¯«°·±d¾Ç­b¡A±À¼sºë¯«°·±dªº²z©À¡A«P¶iªì¯Å¹w¨¾¡C¹ï©ó¬K­·­pµe¡A¦P¤¯§¡¦Õ¼ô¯à¸Ô¡A²w²w¤W¤f¡A¥~¬É¤]µ¹§Ú­Ì«Ü°ªªºµû»ù¡A¦p¦ó¶i¤@¨B¸¨¹ê¡A»Ý­n¤j®a¤@°_µo´§´¼¼z¤Î¼ö§Õ¡C¬F©²¥Ø«e¶}©l±À¼sªø·Ó2.0¡A§Ú­ÌªÀ°Ïºë¯«°·±dÀç³y¡A¥i»Pªø·Óºôµ¸±K¤Áµ²¦X¡Aµo´§²`¯ÑªÀ°Ïªº®ÄªG¡C
¡@¡@¦b¾Ç²ß¬ã¨s¤è­±¡A§Ú­Ìµ¹¤©¦P¤¯¤½°²¦Ü¾Ç®Õ¶i­×¡A§Æ±æ¥i¥H°ö¨|¤H¤~¡A¾Ç¦¨«á¯àÀ³¥Î©óÁ{§ÉªA°È¡A´£¤ÉÂåÀø«~½è¡A«P¶i¾Ç²ß¤§¨}©Ê´`Àô¡C¦P®É§Ú­Ì¤]´£¨Ñ¸g¶O¡A¸É§U¦P¤¯°µÁ{§ÉÀ³¥Î¬ã¨s¡A¥Ø«e§Ú¥H¬°³o¤è­±ªº­·®ðÁÙ¦³«Ý´£¤É¡A¤j®a¤]ÁÙ¨S¦³¾i¦¨±N¬ã¨s¦¨ªG¼g¦¨½×¤åµoªíªº²ßºD¡A¶·«ùÄò¤j¤O±À°Ê¡A¦¨¬°¦W²Å¨ä¹ê¤§¾Ç²ß«¬²Õ´¡C
¡@¡@§Ú¬Û«H¸g¥Ñ³o¤T¦~ªº§V¤O¡A«n§ë¶m¿ËÀ³¸Ó¹ï§Ú­ÌÂå°|´£¨ÑªºªA°È¦³§ó¦nªº¤f¸O¡A§Ú­Ì¦P¤¯À³¸Ó¹ï¦Û¤v¤ÎÂå°|§ó¦³«H¤ß¡A¥H¨­¦b½Ã¥ÍºÖ§Q³¡¯ó¤ÙÀø¾i°|ªA°È¬°ºa¡C¥¼¨Ó´X¦~¡A§Ú­Ì¦bÁ{§ÉªA°È¡BÂåÀø«~½è¡B±Ð¾Ç¤Î¬ã¨s¤è­±¡A¤´µM­nºë¯q¨Dºë¡A¤O¨D¶i¨B¡C´N¥ô¤T¦~¥H¨Ó¡A¥H¹ÅÂÔ°O§Ú­ÌÂå°|ªºÄ@´º¡A¹ï¦P¤¯ªº¼ç¤O¡A¥ç²`¨ã«H¤ß¡A¬Û«H¥u­n¥ß©w¥Ø¼Ð¡A¤èªk¥¿½T¡A¤j®a¦P¤ß»ô¤O¡A«ùÄò±À°Ê¡A¥²¯à©¹¥þ°êºë¯«ÂåÀø¤§¨å½dÁÚ¶i¡A¥´³y¤@¬yªººë¯«¬ì±M¬ì±Ð¾ÇÂå°|¡C

106¦~¬K¸`ªù¶Eªí

¥»°|§Ö°T
106¦~«×¥¢´¼¯g®aÄݤä«ù¹ÎÅé
°Ñ¥[¹ï¶H¡Gªù¶Eº[¦Ñ¦~¤é¶¡¯f©Ð¥¢´¼¯g®aÄÝ
¶i¦æ¤é´Á¡G¨C¤ë²Ä¤T¶g¶g¤»¡A¤W¤È9¡G00-12¡G00
¡]1¤ë¾A³{¹L¦~¼È°±¤@¦¸¡^2/11¡B3/18
¥D¿ì³æ¦ì¡G¦Ñ¦~¤é¶¡¯f©Ð ¦aÂI¡G¦Ñ¦~¤é¶¡¯f©Ð
Ápµ¸¹q¸Ü¡G049-2550800 Âà2204 ¶ÀÄõ´@ ªÀ¤u©Î049-2354681 §d¬î§öÅ@²z®v Åwªï±zªº°Ñ»P


- TOP-


°·±d®Ñ§{ °·±d®Ñ§{
¬K¸`¨¾¬Ì«Å¾É¡@¡@¡@¡@¡@¡@¡@¡@¡@¡@¡@¡@¡@¤å/Å@²z¬ì³¯ÂÔ¾ìÅ@²zªø
¡@¡@©N©N©NÃò¡K©N©N©NÃò¡K¬¶¦Ë¤@Án°£Â·³¡Aª÷Âû·Ç³Æ¨Ó³ø³ß¡C«¦¤@¤U¡A106¦~¹A¾ä¬K¸`§Y±N¨Ó¨ì¡A½¤F¤@¤U¹A¥Á¾ä¡A«z..1¤ë¸`®ð¥¿­È¤j´H°Ú¡A¤]¦]¬°³o¼Ë®ð­Ô¦]¯À¡A¥[¦¨¤F©u¸`©Ê¬y·P¤Î¯f¬r©Ê¸z­Gª¢µ¥°ª¶Ç¬V©Ê¯e¯f¤§±jŧ¡C
µS°O105¦~¬K¸`´Á¶¡¡A©ñ¤F9¤Ñ¦~°²¡A¦UÆ[¥ú³Ó¦a¡B¦W³Ó¥jÂÝ´X¥G³£¬Oº¡º¡¤H¼é¡A¦b¤H¼é¾ÖÀ½¤Î®ð­Ô¼vÅT¤U¡A¨Ï±o¦UÂå°|ªù«æ¶E¡AÃþ¬y·P¯f¨Ò¦Ê¤À¤ñ¹F¨ì°ª®p¡A¸û103¡B104¦~¦P®É´Á¤j´T¤W¤É¡A¤×¨ä¬O¬y·P¨Öµo­«¯g®×¨Ò¼Æ¼W¥[¡A¤]Åý³\¦hÂå°|Á^ºò¯«¸g¡B¯h©ó©b©R¡C
¯f¬r©Ê¸z­Gª¢¤]¤£´q¦hÅý¡A¬K¸`´Á¶¡¡A¨ì³B¹Cª±¡A¦Y³Ü¤U¡A¥¼ª`·N­¹ª«²M¼ä©Î²¨©¿½Ã¥Í²ßºD®É¡A´N®e©ö¾É­P¯f­ì¶Ç¼½¡C¾Ú¯eºÞ¸p²Î­p¸ê®ÆÅã¥Ü¡A102-104¦~¬K¸`´Á¶¡¡A¥­§¡¯f¬r©Ê¸z­Gª¢´N¶E¤H¦¸§¡¤W¸U°_¸õ¡A¤À§O¬°36,175¡B40,938¡B50,683¡A¦]¦¹¡A¥H¤U´N°w¹ï¬y·P¤Î¯f¬r©Ê¸z­Gª¢¡A¬°¦U¦ì°µ­Ó²³æ¤¶²Ð:
¤@¡B¬y·P:
´N¬O¬y¦æ©Ê·P«_²ºÙ¡A¨ã¦³©úÅã©u¸`©Ê¯S¼x¡A¥D­n­P¯f­ì¬°¬y·P¯f¬r¡AÁ{§É¤W©Ò¿×·P«_¡B³ïª¢¡B¤ä®ðºÞª¢¡B¯f¬r©ÊªÍª¢§¡¦³¥i¯à¬°·P¬V¬y·P¯f¬r©Ò¤Þ°_¡C
¶Ç¬V³~®|:­¸ªj¤Î±µÄ²¶Ç¬V¡C
¥D­n¯gª¬:µo¿N¡BÀYµh¡B¦Ù¦×µh¡B¯h­Â¡B¬y»ó®÷¡B³ïÄVµh¤Î«y¹Âµ¥¡A³¡¤À¦ñ¦³¸¡Âm¡B¹Ã¦R¡C
¤G¡B¯f¬r©Ê¸z­Gª¢:
¸z­Gª¢«Y«ü­G¡B¤p¸z©Î¤j¸zµoª¢¡A¾É­P¹Ã¦R©Î¸¡Âm¡C¥xÆW¿Õù¯f¬r¤Î½üª¬¯f¬r¥D­n¬y¦æ©u¸`¬°11¤ë¨ì¹j¦~3¤ë¶¡¡C
¶Ç¬V³~®|: ³z¹LÁT¤f³~®|¡A©Î§l¤J¯f¤H¹Ã¦Rª«¤Î±Æªnª«©Ò²£¥Í­¸ªj¡C ¥D­n¯gª¬: ¤ôÂm©M¹Ã¦R¡C¤]¥i¯à¦³ÀYµh¡Bµo¿N¡B­Gµh¡Bäú¤ß¡B¦Ù¦×»Äµh¡C
¬K¸`´Á¶¡¡A¬°®a®a¹Î¶ê¤§¤é¡A¯f¤H»PªÀ°Ï±µÄ²®É¶¡ÅܱoÀWÁc¡A¤]®e©ö±NªÀ°Ï¥Ø«e¥¿¦b¬y¦æªº¯e¯f±a¦^¯f©Ð¤¤¡A¥B®e©ö¦]¦~Ä֦ѤơB¦Û§Ú·ÓÅU¯à¤O®t¡A¤Î±K¶°©ÊªÅ¶¡¦]¯À¡A¦Ó§Ö³t¶Ç¼½¡A¨ÃÅý¯fµ{©µªø¡A¨ä¹ê³z¹L¤p¤pª`·N¡A¨Æ¥ý¶i¦æ¹w¨¾¡A¬O¥i¥H¦³®Ä±±¨î¶Ç¬V©Ê¯e¯fªºÃzµo:
¦@³q­ì«h:
1.ª`·N©I§l¹D¤Î«y¹Â§¸`:±j¯P«ØÄ³À¹¤W¤f¸n¡A«OÅ@¦Û¤v¤Î¥L¤H¡C
2.±`¬~¤â:»Ýª`·N¿Õù¤Î¸z¯f¬r¨Ï¥Î°®¬~¤â²G¬OµL®Äªº³á¡C
3.¶¼­¹³¡¤À:¤Å¥Í­¹¡B¥Í¶¼¡B¤Å¦@­¹¡C
4.°·±dºÊ´úºÞ²z:­Y±z¾D·P¬V¡AºÉ§Ö´NÂå¡A¦h¥ð®§¡A¤£¤W¯Z¡C
5.¬Ì­]±µºØ:±µºØ¬y·P¬Ì­]¤£¥Nªí¤£·|·P«_¡A¦ý¥iÁ×§K·P¬V¬y·P­«¯g¡A½Ð§â´¤±µºØ¡C
¯f©Ð·ÓÅ@³¡¤À:
1.¸¨¹ê³X«ÈºÞ²z:¨Ó³X®aÄÝ­Y¦³¤W©I§l¹D¯gª¬®É¡A½Ð¥D°Ê´£¨Ñ¤f¸n¡A«ØÄ³¼È½w±´µø©ÎÁYµu·|«È®É¶¡¡C
2.¯f¤H¥~±J¡B¥~¥X©Î¤u§@ªð«Ç«á¡A¸¨¹ê¬~¤â¡AºÊ´ú¦³µL·P¬V¯gª¬¡A©Î¸ß°Ý©Ò¦bÀô¹Ò¦³µL®aÄݩΤu§@¤H­û¦³·P¬V¯gª¬¡C
3.­Y¯f¤H¤w¥X²{·P¬V¯gª¬®É¡A¾A·í¹jÂ÷¡A·ÓÅ@¤H­û»ÝÀ¹¤W¨¾Å@¸Ë³Æ¡A¦p¤f¸n©Î¤â®M¡A¹ý©³°õ¦æÀô¹Ò²M¼ä¤Î®ø¬r¡C

¦Ñ¤HÃĨƷÓÅ@²L½Í¡X§ÜÁxÆPÃĪ«¡@¡@¡@¡@¡@¡@¡@¡@¡@¡@¤å/Ãľ¯¬ì¾G¬°¤¸ÃÄ®v
¡@¡@°ªÄ֤ƦѤH¥ÎÃĭȱoÃöª`¡C»OÆW±q1993¦~°_¥¿¦¡ÁÚ¤J°ªÄ֤ƪÀ·|¡]Ageing Society¡^¡A2013¦~12¤ë¡A65·³¥H¤W¤H¤f¶W¹L269¸U¤H¡A¶W¹LÁ`¤H¤fªº11.5¢H¡C¹w­p2018¦~65·³¥H¤W¤H¤f±N¹F14¢H¡A¹F¨ì°ê»ÚºD¨Ò©ÒºÙªº°ªÄÖªÀ·|¡]Aged Society¡^¡C±À¦ô¨ì2025¦~¡A»OÆW65·³¥H¤W¤H¤f¬ù20¢H¡AÁÚ¤J¶W°ªÄÖªÀ·|¡]Super Aged Society¡^¡A¥B¦Ñ¤Æ³t«×±N¬°²{¦³¦U¤w¶}µo°ê®a¤¤³Ì§ÖªÌ(¤º¬F³¡²Î­p³B¡A2015)¡C
¦Ñ¤H¥Í²z¾÷¯à°I°h¤S¿©±w¦hºØ¯e¯f¦Ñ¤H±`¨Ï¥Î¦hºØÃĪ«¡A·í¥ÎÃĪº¼Æ¥Ø¥Ñ¤@ºØ¼W¥[¦Ü¤GºØ®É¡Aµo¥ÍÃĪ«¤£¨}¨Æ¥óªº¾÷²v·|¼W¥[¬°13%¡F­Y¨Ï¥Î¤­ºØÃĪ«¡Aµo¥ÍÃĪ«¤£¨}¨Æ¥óªº¾÷²v·|¼W¥[¬°58%¡F¤@¥¹¨Ï¥ÎÃĪ«¹F¨ì¤CºØ¥H¤W¡Aµo¥ÍÃĪ«¤£¨}¨Æ¥óªº¾÷²v«h°ª¹F¬°82%(Clyne et al., 2012)¡C¦Ñ¤Hªø¦~(3¦~¥H¤W)°ª¾¯¶q§ÜÁxÆPÃĪ«¼W¥[¤F50-60%¥ÎÃÄ­·ÀI¡AªvÀø¤WÀ³À£§C¦Ü³Ì¤Öªº¦³®Ä¾¯¶q(Gray et al., 2015)¡C¦Ñ¤H¹ï§ÜÁxÆPÃĪ«¦³®t²§©Ê¡C¦Ñ¤H¹ï§ÜÁxÆPÃĪ«¤ñ¤@¯ë¤H·P¨ü©Ê§ó¤j¬O¦]¬°¨üpharmacokinetic(¾¯¶q¡A¿@«×)¤Îpharmacodynamic(ÃĮġA§@¥Î¾÷Âà)ªº¦]¯À¦Ó¦³©Ò¤£¦P(de Leon,2011)¡C­ì¦]¬O¦Ñ¤H¨xŦ¤ÎµÇŦ¥NÁ¤U­°¡A¹ïÃĪ«³q¹LBBB(¦å¸£»Ù½ª)³q³z©Ê¸û°ª(Shi&Klotz, 2011) §ÜÁxÆPÃĪ«(Anticholinergic drugs)³o­Ó¤ÀÃþªºÃĪ«¡A¦bÁ{§É¤Wªº¨Ï¥Î«Ü¼s¤S«ÜÀWÁc(Gerretsen et al., 2011)¡C¦Ñ¤H¦b§Ü¹L±Ó§Ü¼~Æ{¾¯§ÜµjÅË©ÊÃĪ«Beers criteria«ü¥XªvÀø¦Ñ¦~¤H¹L±Ó¤ÏÀ³¡AÀ³Àu¥ý¿ï¥Î¤£¨ã§ÜÁxÆP©Ê½èªº§Ü²Õ´ÓiÃĪ«¡A¦ploratadine (Finska)¡Bcetirizine (Cerin)¡Bfexofenadine (Allegra )¤Îazelastine (Astelin)¡C¨ä¤¤¥H©ö³q¹L¦å¸£»Ù¾Àªº§Ü²Õ´ÓiDiphenhydramine¡A³Ì©ö³y¦¨ÂíÀR»Pºë¯«²V¶Ã¡A¤£À³§@¬°¦w¯vÃĨϥΡC³\¦h¬ã¨s³£«ü¥X¦Ñ¦~¤HÀ³Á×§K¨Ï¥Î¤TÀô§Ü¼~Æ{¾¯¡A¦]¬°¦b¤@¯ëªvÀø¿@«×¤U¨ä§ÜÁxÆP°Æ§@¥Î¤j¡A¨ä¤¤¤S¥H¤T¯ÅÓiµ²ºcªº¤TÀô§Ü¼~Æ{¾¯(¦pamitriptyline (Elavil, Endep)¡Bimipramine (Tofranil)¡Bdoxepin (Sinequan))¸û©ö¹L¦å¸£«Ì½ª¡A¸û±`²£¥Í¤¤¼Ï°Æ§@¥Î(Domenic AC et al., 2004;Lon SS et al., 1994) ¡C»H¯Ö¹L°Ê¯g¡A±`¹B¥Î¤fªA§ÜÁxÆPÃĪ«¡A¦ppropantheline¡Boxybutynin¡Bflavoxate¡Btolterodineµ¥¡A¨ÓªýÂ_»H¯Ö­¢§¿¦Ù¤W¤AñQÁxÆP±µ¨ü¾¹¡A´î¤Ö­¢§¿¦Ùªº¦¬ÁY±i¤O¦ÓÃP¦¢¡A¨Ã¼W¥[»H¯Ö®e¶q´î¤Ö±Æ§¿¡C¨ä¤¤¥Hpropantheline®ÄªG³Ì¦n¡A¦ý¤]³Ì©ö³y¦¨¦Ñ¦~¤Hºë¯«¯¿¶Ã¡A¨ä¥L³t®Ä«¬§ÜÁxÆPÃĪ««h¥ç³y¦¨¤¤¦Ü­««×¤f°®¡BÂíÀR¡A¨Ï¦Ñ¦~¤H¹ï©ó¤j³¡¤Àªº¦Ù¦×ÃP¦¢¾¯©M§ÜµjÅ˾¯­@¨ü©Ê¤£¨Î(Shah D et al., 2002)¡A°©Àf¦ÙµjÅ˱`¥ÎÃĤ¤¥Horphenadrine (Norflex)³Ì©ö¤Þ°_§ÜÁxÆP¤ÎÂíÀR°Æ§@¥Î¡A¦Ñ¤H­n·V¥Î¡C
¦Ñ¤H¸û©ö¨Ï¥Î¦hºØÃĪ«¡C¦b¬ü°ê±w¦h­«¯e¯fªº²±¦æ²v¬°1.38%¡A¦Ó¨ä¤¤40%¤S¬O¤TºØ©Î¤TºØ¥H¤W¯e¯fªº¦Ñ¤H¡]Remires-Duque et al., 2008)¡C¬ã¨s«ü¥X¦Ñ¤H¦hºØ¯e¯f¾É­P¦h­«¥ÎÃÄ¡A¦Ñ¤H±`¶}¥ßªºÃĪ«ºØÃþ¨Ò¦p:§Ü¼~Æ{ÃÄ¡B§Üºë¯«ÃÄ¡B©¬ª÷´ËÃÄ¡B¦Ù¦×ÃP¦¢¾¯¡B§Ü¹L±ÓÃÄ¡B¨î»Ä¾¯¡B¤î¦R§Ü·wÃÄ¡B¸z­G²§±`į°ÊÃÄ¡B»H¯ÖÄáÅ@¸¢¥ÎÃÄ¡A©Ò¶}¥ß³B¤è¤j¦h³£§t¦³§ÜÁxÆP¬¡©Ê(anticholinergic effects)¡B©Ò¥H¦Ñ¤HÃnÅS¦b§ÜÁxÆPÃĪ«­·ÀI¤ñ¤@¯ë¤H°ª¡]Bostock et al., 2010)¡C±Nªñ50%ªº¦Ñ¤Hªø´ÁªA¥Î¤@ºØ¥H¤W¦³¼ç¦b¤£·í¥ÎÃĤ§§ÜÁxÆPÃĪ«¡]Fox et al., 2011¡FMaher et al., 2014¡^¡C
¦Ñ¤H¼ç¦b©Ê¤£·í¥ÎÃÄÄY­«¡A¨ä¤¤§ÜÁxÆPÃĪ«¼ç¦b¤£¾A·í¥ÎÃÄ(PIADs)¦û¤£¦b¤Ö¼Æ¡C65·³¥H¤Wªºªù¶E¦Ñ¦~¯f¤H¡Aµo²{§t¦³¼ç¦b©Ê¤£¾A·íÃĪ«¤§²±¦æ²v¬°19.1%(Lai et al., 2009)¡C§Q¥ÎPIM-Taiwan¬ã¨sµo²{65·³¥H¤W¦í¥ÁªºPIM(¼ç¦b©Ê¤£¾A·íÃĪ«)²±¦æ²v¬°63.04%¡C¨ä¤¤1¦Ü5ºØ¤£·í¥ÎÃÄ¥e33.34%¡F6¦Ü10ºØ¬°13.11%¡F¤j©ó10ºØ¬°16.59%(Chang et al., 2014)¡C°ê¤º¦Ñ¤H¼ç¦b©Ê¤£¾A·í¥ÎÃIJ±¦æ²v¤j©ó°ê¥~¬GÀ³ÂÔ·V³B¤è¥H½T«O»Ý­nªø´ÁªAÃĪººC©Ê¯f¦Ñ¦~¤H°·±d¤Î¥ÎÃĦw¥þ(½²ªF¿«, 2011)¡C¸­«í¨} ( 2010)°ê¤º¬ã¨s´£¤Îªù¶E老年¯f±w±µ¨ü»P¶EÂ_µLÃö¤§¡u¼ç¦b不¾A切¥ÎÃÄ¡v³B¤è±¡§Î¡v¥i¥H¬Ý¥X¡A¤j¬ù¦³ªñ¤T¤À¤§¤@(32.47%)ªº老年¯f±w±µ¨ü了¡u¨ã§ÜÁxÆP§@¥Î¤§§Ü²Õ´Ói(Antihistamines with anticholinergic effects)¡v³o類ªº¼ç¦b不¾A切¥ÎÃÄ¡C¥t°ê¤º¬ã¨sµo²{¥xÆW¦Ñ¦~¤H§ÜÁxÆPÃĪ«¼ç¦b¤£¾A·í¥ÎÃÄ(PIADs)¤§³B¤è²±¦æ²v¬°18.67%¡A¦ý¦Ü¤Ö¦³75.65%ªº¦Ñ¦~¤H´¿¸g±µ¨ü¹L¦Ü¤Ö¤@¦¸¤§§ÜÁxÆP¼ç¦b¤£¾A·í¥ÎÃÄ¡A¦b±±¨î¨ä¥L¬ÛÃö¼vÅT¦]¯À«á¡Aµo²{§ÜÁxÆP¼ç¦b¤£¾A·í¥ÎÃĪ̬۸û©óµL§ÜÁxÆP¼ç¦b¤£¾A·í¥ÎÃĪ̡A¨ä«æ¶E¤§¬Û¹ï¦MÀI©Ê¬°1.85­¿¡F¦í°|¤§¬Û¹ï¦MÀI©Ê¬°1.07­¿(¶À¥úµØ, 2012)¡C°ê¥~¬ã¨sµo²{¦³64%ªº¦Ñ¦~¤H´¿¸g±µ¨ü¹L¦Ü¤Ö¤@¦¸¤§§ÜÁxÆP¼ç¦b¤£¾A·í¥ÎÃÄ(Paul et al., 2015)¡C
¾A®ÉªºÃĨƤ¶¤J½T¹ê¥i´£°ª¦Ñ¤Hªº¥ÎÃĦw¥þ¡A¤×¨ä¬OÁÚ¤J°ªÄÖªºÀø¾i°|¯f¤H¡A¦Ó¥xÆW³B¤è«¬ºA¤Î¥ÎÃÄÀô¹Ò»P°ê¥~¤£¦P¡A¥B¥xÆW¦Ñ¦~¯f±w§ÜÁxÆP¥ÎÃĤ£¾A·í¤§µo¥Í²v¬Û¸û°ê¥~¨Ó±o°ª¡C¦Ó§ÜÁxÆPÃĪ«©Ò­l¥Í¤§ªvÀø­·ÀI¡A½T¹ê¬O¤@­Ó­È±o²`¨sªº°ÝÃD¡C

°Ñ¦Ò¸ê®Æ
Almirall, J., Bolibar, I., Serra-Prat, M., Roig, J., Hospital, I., Carandell, E., . . . Community-Acquired Pneumonia in Catalan Countries Study, G. (2008). New evidence of risk factors for community-acquired pneumonia: a population-based study. Eur Respir J, 31(6), 1274-1284. Chang C-B, Lai H-Y, Yang S-Y, Wu R-S, Liu H-C, Hsu H-Y, et al. (2014) Patient- and Clinic Visit-Related Factors Associated with Potentially Inappropriate Medication Use among Older Home Healthcare Service Recipients. PLoS ONE 9(4): e94350.
Dublin S, Walker RL, Jackson ML et al. Use of opioids or benzodiazepinesand risk of pneumonia in older adults: A population-based case-controlstudy. J Am Geriatr Soc 2011;59:1899¡V1907.
Duran CE, Azermai M, Vander Stichele R. Systematic review of anticholinergicrisk scales in older adults. Response to letter of the editor. Eur J ClinPharmacol 2013;69:1731. Fox C, Richardson K, Maidment ID, Savva GM, Matthews FE, Smithard D, Coulton S, Katona C, Boustani MA, Brayne C. Anticholinergic medication use and cognitive impairment in the older population: the medical research council cognitive function and ageing study. J Am Geriatr Soc. 2011 ;59(8):1477-83.
Paul, K. J., Walker, R. L., & Dublin, S. (2015). Anticholinergic medications and risk of community-acquired pneumonia in elderly adults: a population-based case-control study. J Am Geriatr Soc, 63(3), 476-485. doi:10.1111/jgs.13327
¸­ùÚ¨}. (2010). ¥xÆW¦Ñ¦~¤H¼ç¦b¤£¾A¤Á¥ÎÃÄ»P¼vÅT¦]¯À¤§¬ã¨s. (ºÓ¤h), °ê¥ß¶§©ú¤j¾Ç, ¥x¥_¥«. ¶À¥úµØ(Kuang-Hua Huang)¡B¸â©ÉªÚ(YI- FANG CHAN)¡B¬I§»­õ(HUNG-CHE SHIH)¡B§õ«Ø¼ü(CHIEN-YING LEE)*¡ARelationship between Potentially Inappropriate Anticholinergic Drugs (PIADs) and Adverse Outcomes among Elderly Patients in Taiwan¡AJOURNAL OF FOOD AND DRUG ANALYSIS¡A2012 Dec¡A20(4):930-937¡ASCI


- TOP-

106¦~1¤ë¥÷ªù¶E½Ã¥ÍÁ¿®yº[¾Ç³N¬¡°Ê 106¦~1¤ë¥÷ªù¶E½Ã¥ÍÁ¿®yº[¾Ç³N¬¡°Ê
106¦~1¤ë¥÷ªù¶E½Ã¥ÍÁ¿®y
¤é´Á¡@¡@¬P´Á¡@¡@¡@®É¶¡¡@¡@¡@¡@¡@¡@¡@¡@¥DÃD¡@¡@¡@¡@¡@¡@¥DÁ¿¤H
¡×¡×¡×¡×¡×¡×¡×¡×¡×¡×¡×¡×¡×¡×¡×¡×¡×¡×¡×¡×¡×¡×¡×¡×¡×¡×¡×¡×¡×¡×¡×¡×¡×
01/04¡@¤T¡@¡@10¡G00¡ã10¡G30¡@ºë¯«¬ì¥ÎÃı`¨£°Æ§@¥Î³B²z¤è¦¡¡@¦¿¬F¾ÈÃÄ®v
01/06¡@¤­¡@¡@09¡G00¡ã09¡G30¡@»{ÃѤT°ª¡@¡@¡@¡@¡@¡@¡@¡@¡@¡@ÁµµÁ¨Å@²z®v
01/11¡@¤T¡@¡@09¡G00¡ã10¡G00¡@ªÀ·|ºÖ§Q¸ê·½¤¶²Ð-¾¹©x®½ÃØ¡@¡@¶À´f±ÓªÀ¤u®v
01/12¡@¥|¡@¡@09¡G00¡ã09¡G30¡@¦V¥¢¯v»¡±ß¦w¡@¡@¡@¡@¡@¡@¡@¡@©P¬M§±¤ß²z®v
01/16¡@¤@¡@¡@09¡G00¡ã09¡G30¡@¦p¦ó¼W¶i¤H»Ú¤¬°Ê¡@¡@¡@¡@¡@¡@­ð¸Öµ^Å@²z®v
01/17¡@¤G¡@¡@09¡G30¡ã10¡G00¡@«O©R¨¾¶^¤¶²Ð¡@¡@¡@¡@¡@¡@¤ý¨K¤ªÂ¾¯àªvÀø®v
01/18¡@¤T¡@¡@09¡G00¡ã09¡G30¡@©~®aªvÀøÂ²¤¶¡@¡@¡@¡@¡@¡@¡@¡@§d¨ÎªâÅ@²z®v
01/20¡@¤­¡@¡@09¡G00¡ã09¡G30¡@¤@®ñ¤ÆºÒ¤¤¬r¹w¨¾¤Îpm2.5¤¶²Ð¡@¬x¬ü¥ÉÅ@²z®v
¡×¡×¡×¡×¡×¡×¡×¡×¡×¡×¡×¡×¡×¡×¡×¡×¡×¡×¡×¡×¡×¡×¡×¡×¡×¡×¡×¡×¡×¡×¡×¡×¡×
¾Ç³N¬¡°Ê

®É¶¡¡G106¦~1¤ë5¤é¡]¶g¥|¡^13:30-15:30
¦aÂI¡G²¦¦Ü¼Ó®æ­PÆU
¥DÃD¡Gºë¯«¯e¯fªº¦@¯f¬ã¨s»PÁ{§ÉÀ³¥Î
Á¿®v¡G²¥H¹Å°|ªø

®É¶¡¡G106¦~1¤ë12¤é¡]¶g¥|¡^13:30-15:30
¦aÂI¡G²¦¦Ü¼Ó®æ­PÆU
¥DÃD¡G¥DªvÂå®vºtÁ¿
Á¿®v¡GªL·ÉÄ£¥D¥ô

®É¶¡¡G106¦~1¤ë19¤é¡]¶g¥|¡^13:30-15:30
¦aÂI¡G²¦¦Ü¼Ó®æ­PÆU
¥DÃD¡G¥þ°|­Ó®×°Q½×·|
³ø§iªÌ:¶À«Û³ÔÂå®v
¥D«ù¤H:³¯«p¨}Âå®v
·|½ÍªÌ:¤ý´^¦~Âå®v


- TOP-


106¦~1¤ë¥»°|ªù¶Eªí 106¦~1¤ë¥»°|ªù¶Eªí
106¦~1¤ë¥»°|ªù¶Eªí

106¦~1¤ëªÀ°Ïªù¶Eªí



- TOP-


­¶§À­I´º¹Ï